What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Autoimmune Disease Orphan Drug

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307749

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307749

APAC Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

PUBLISHED: June 1, 2023

PAGES: 194 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Asia-Pacific pemphigus vulgaris market is expected to reach USD 115.59 million by 2030 from USD 57.14 million in 2022, growing at a CAGR of 9.3% during the forecast period of 2023 to 2030.

Market Segmentation:

Asia-Pacific Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Pemphigus Vulgaris Market Dynamics:

Driver
Rise in patients with rare diseases such as pemphigus vulgaris
Restraint
High cost of treatment
Opportunity
Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the market are:

Johnson & Johnson Services, Inc.
RAKSHIT DRUGS PVT. LTD
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Celltrion Healthcare Co., Ltd.
Teva Pharmaceutical Industries Ltd
Lilly
Zydus Group
GSK plc.

1 INTRODUCTION 31

1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33

2 MARKET SEGMENTATION 36

2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.6 MULTIVARIATE MODELLING 43
2.7 MARKET APPLICATION COVERAGE GRID 44
2.8 PRODUCT LIFELINE CURVE 45
2.9 DBMR MARKET POSITION GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PESTEL ANALYSIS 52
4.2 PORTER FIVE FORCES 53
4.3 PATENT ANALYSIS 54
4.4 PATIENT FLOW DIAGRAM 55
4.5 KEY PRICING STRATEGIES 56
4.6 FUTURE THERAPIES 57
4.7 KEY PATIENT ENROLLMENT STRATEGIES 58

5 PIPELINE ANALYSIS 59

6 EPIDEMIOLOGY 60

7 INDUSTRY INSIGHTS 61

8 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: REGULATIONS 62

9 MARKET OVERVIEW 65

9.1 DRIVERS 67
- 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
- 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
- 9.1.3 AWARENESS REGARDING THE DISEASE 68
9.2 RESTRAINTS 68
- 9.2.1 STRICT REGULATORY GUIDELINES 68
- 9.2.2 HIGH TREATMENT COSTS 68
9.3 OPPORTUNITIES 69
- 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
- 9.3.2 INCREASING HEALTHCARE FACILITIES 69
- 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
9.4 CHALLENGES 70
- 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
- 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71

10 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72

10.1 OVERVIEW 73
10.2 TREATMENT 76
- 10.2.1 MEDICATIONS, BY TYPE 76
  - 10.2.1.1 CORTICOSTEROIDS 77
  - 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
    - 10.2.1.2.1 AZATHIOPRINE 78
    - 10.2.1.2.2 MYCOPHENALATE MOFETIL 78
    - 10.2.1.2.3 METHOTREXATE 78
    - 10.2.1.2.4 CYCLOPHOSPHAMIDE 78
    - 10.2.1.2.5 MIZORIBINE 78
    - 10.2.1.2.6 OTHERS 78
  - 10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
    - 10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
    - 10.2.1.3.2 TETRACYCLINE 79
    - 10.2.1.3.3 OTHERS 79
  - 10.2.1.4 BIOLOGICS 79
  - 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
  - 10.2.1.6 ANTIBIOTICS 79
  - 10.2.1.7 ANTIFUNGALS 79
  - 10.2.1.8 ANTIVIRALS 79
  - 10.2.1.9 OTHER MEDICATIONS 79
- 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
  - 10.2.2.1 ORAL 80
  - 10.2.2.2 TOPICAL 80
  - 10.2.2.3 PARENTERAL 80
  - 10.2.2.4 OTHERS 80
- 10.2.3 MEDICATIONS, BY DRUG TYPE 80
  - 10.2.3.1 GENERIC 81
  - 10.2.3.2 BRANDED 81
10.3 DIAGNOSIS 81
- 10.3.1 SKIN BIOPSY 82
- 10.3.2 BLOOD TEST 82
- 10.3.3 ENDOSCOPY 82

11 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83

11.1 OVERVIEW 84
11.2 ADULTS 87
11.3 GERIATRIC 88
11.4 PEDIATRIC 89

12 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 90

12.1 OVERVIEW 91
12.2 HOSPITALS 94
12.3 SPECIALTY CLINICS 94
12.4 RESEARCH INSTITUTES 95
12.5 OTHERS 96

13 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97

13.1 OVERVIEW 98
13.2 HOSPITALS PHARMACY 101
13.3 RETAIL PHARMACY 101
13.4 ONLINE PHARMACY 102

14 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY REGION 103

14.1 ASIA-PACIFIC 104
- 14.1.1 CHINA 113
- 14.1.2 INDIA 117
- 14.1.3 SOUTH KOREA 121
- 14.1.4 MALAYSIA 125
- 14.1.5 JAPAN 129
- 14.1.6 AUSTRALIA 133
- 14.1.7 SINGAPORE 137
- 14.1.8 THAILAND 141
- 14.1.9 INDONESIA 145
- 14.1.10 PHILIPPINES 149
- 14.1.11 REST OF ASIA-PACIFIC 152

15 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 153

15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 153

16 SWOT ANALYSIS 154

17 COMPANY PROFILE 155

17.1 ABBVIE INC. 155
- 17.1.1 COMPANY SNAPSHOT 155
- 17.1.2 REVENUE ANALYSIS 155
- 17.1.3 COMPANY SHARE ANALYSIS 156
- 17.1.4 PRODUCT PORTFOLIO 156
- 17.1.5 RECENT DEVELOPMENTS 157
17.2 MERCK & CO., INC., 158
- 17.2.1 COMPANY SNAPSHOT 158
- 17.2.2 REVENUE ANALYSIS 158
- 17.2.3 COMPANY SHARE ANALYSIS 159
- 17.2.4 PRODUCT PORTFOLIO 159
- 17.2.5 RECENT DEVELOPMENT 159
17.3 SANOFI 160
- 17.3.1 COMPANY SNAPSHOT 160
- 17.3.2 REVENUE ANALYSIS 160
- 17.3.3 COMPANY SHARE ANALYSIS 161
- 17.3.4 PRODUCT PORTFOLIO 161
- 17.3.5 RECENT DEVELOPMENT 161
17.4 REGENERON PHARMACEUTICALS INC. 162
- 17.4.1 COMPANY SNAPSHOT 162
- 17.4.2 REVENUE ANALYSIS 162
- 17.4.3 COMPANY SHARE ANALYSIS 163
- 17.4.4 PRODUCT PORTFOLIO 163
- 17.4.5 RECENT DEVELOPMENT 163
17.5 NOVARTIS AG 164
- 17.5.1 COMPANY SNAPSHOT 164
- 17.5.2 REVENUE ANALYSIS 164
- 17.5.3 COMPANY SHARE ANALYSIS 165
- 17.5.4 PRODUCT PORTFOLIO 165
- 17.5.5 RECENT DEVELOPMENT 165
17.6 AMGEN INC. 166
- 17.6.1 COMPANY SNAPSHOT 166
- 17.6.2 REVENUE ANALYSIS 166
- 17.6.3 PRODUCT PORTFOLIO 167
- 17.6.4 RECENT DEVELOPMENTS 167
17.7 ASTRAZENECA 168
- 17.7.1 COMPANY SNAPSHOT 168
- 17.7.2 REVENUE ANALYSIS 168
- 17.7.3 COMPANY SHARE ANALYSIS 169
- 17.7.4 PRODUCT PORTFOLIO 169
- 17.7.5 RECENT DEVELOPMENTS 170
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 171
- 17.8.1 COMPANY SNAPSHOT 171
- 17.8.2 REVENUE ANALYSIS 171
- 17.8.3 PRODUCT PORTFOLIO 172
- 17.8.4 RECENT DEVELOPMENT 172
17.9 CELLTRION HEALTHCARE CO., LTD 173
- 17.9.1 COMPANY SNAPSHOT 173
- 17.9.2 REVENUE ANALYSIS 173
- 17.9.3 PRODUCT PORTFOLIO 174
- 17.9.4 RECENT DEVELOPMENTS 174
17.10 F. HOFFMANN- LA ROCHE LTD. 175
- 17.10.1 COMPANY SNAPSHOT 175
- 17.10.2 REVENUE ANALYSIS 175
- 17.10.3 PRODUCT PORTFOLIO 176
- 17.10.4 RECENT DEVELOPMENT 176
17.11 FRESENIUS KABI AG 177
- 17.11.1 COMPANY SNAPSHOT 177
- 17.11.2 REVENUE ANALYSIS 177
- 17.11.3 PRODUCT PORTFOLIO 178
- 17.11.4 RECENT DEVELOPMENT 178
17.12 GSK PLC 179
- 17.12.1 COMPANY SNAPSHOT 179
- 17.12.2 REVENUE ANALYSIS 179
- 17.12.3 PRODUCT PORTFOLIO 180
- 17.12.4 RECENT DEVELOPMENT 180
17.13 JOHNSON & JOHNSON SERVICES, INC. 181
- 17.13.1 COMPANY SNAPSHOT 181
- 17.13.2 REVENUE ANALYSIS 181
- 17.13.3 COMPANY SHARE ANALYSIS 182
- 17.13.4 PRODUCT PORTFOLIO 182
- 17.13.5 RECENT DEVELOPMENT 182
17.14 LILLY 183
- 17.14.1 COMPANY SNAPSHOT 183
- 17.14.2 REVENUE ANALYSIS 183
- 17.14.3 PRODUCT PORTFOLIO 184
- 17.14.4 RECENT DEVELOPMENT 184
17.15 PFIZER INC. 185
- 17.15.1 COMPANY SNAPSHOT 185
- 17.15.2 REVENUE ANALYSIS 185
- 17.15.3 PRODUCT PORTFOLIO 186
- 17.15.4 RECENT DEVELOPMENT 186
17.16 RAKSHIT DRUGS PVT. LTD 187
- 17.16.1 COMPANY SNAPSHOT 187
- 17.16.2 PRODUCT PORTFOLIO 187
- 17.16.3 RECENT DEVELOPMENT 187
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 188
- 17.17.1 COMPANY SNAPSHOT 188
- 17.17.2 REVENUE ANALYSIS 188
- 17.17.3 PRODUCT PORTFOLIO 189
- 17.17.4 RECENT DEVELOPMENT 189
17.18 ZYDUS GROUP 190
- 17.18.1 COMPANY SNAPSHOT 190
- 17.18.2 REVENUE ANALYSIS 190
- 17.18.3 PRODUCT PORTFOLIO 191
- 17.18.4 RECENT DEVELOPMENT 191

18 QUESTIONNAIRE 192

19 RELATED REPORTS 194

LIST OF TABLES

TABLE 1 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 42
TABLE 2 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 47
TABLE 3 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 63
TABLE 4 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 5 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
TABLE 6 ASIA PACIFIC STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
TABLE 7 ASIA PACIFIC ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 66
TABLE 8 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 68
TABLE 9 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 68
TABLE 10 ASIA PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 11 ASIA PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 70
TABLE 12 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 74
TABLE 13 ASIA PACIFIC ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 14 ASIA PACIFIC GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 15 ASIA PACIFIC PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 16 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 81
TABLE 17 ASIA PACIFIC HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 18 ASIA PACIFIC SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 19 ASIA PACIFIC RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 20 ASIA PACIFIC OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 21 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 88
TABLE 22 ASIA PACIFIC HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 23 ASIA PACIFIC RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 24 ASIA PACIFIC ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 25 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 96
TABLE 26 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 96
TABLE 27 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
TABLE 28 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
TABLE 29 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
TABLE 30 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 98
TABLE 31 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 98
TABLE 32 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
TABLE 33 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 99
TABLE 34 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 99
TABLE 35 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 100
TABLE 36 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 101
TABLE 37 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
TABLE 38 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
TABLE 39 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
TABLE 40 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 102
TABLE 41 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 103
TABLE 42 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
TABLE 43 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 103
TABLE 44 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 45 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 104
TABLE 46 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 105
TABLE 47 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 48 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 49 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 50 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 106
TABLE 51 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 107
TABLE 52 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
TABLE 53 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 107
TABLE 54 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 107
TABLE 55 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108
TABLE 56 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 109
TABLE 57 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
TABLE 58 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
TABLE 59 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
TABLE 60 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 110
TABLE 61 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 111
TABLE 62 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
TABLE 63 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 111
TABLE 64 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
TABLE 65 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 112
TABLE 66 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 113
TABLE 67 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
TABLE 68 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
TABLE 69 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
TABLE 70 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 114
TABLE 71 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 115
TABLE 72 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
TABLE 73 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 115
TABLE 74 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 116
TABLE 75 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 116
TABLE 76 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 117
TABLE 77 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 78 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 79 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 80 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 118
TABLE 81 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
TABLE 82 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
TABLE 83 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 119
TABLE 84 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 119
TABLE 85 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 120
TABLE 86 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 121
TABLE 87 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
TABLE 88 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 89 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 90 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 122
TABLE 91 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 123
TABLE 92 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 93 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 123
TABLE 94 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
TABLE 95 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 124
TABLE 96 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 125
TABLE 97 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
TABLE 98 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
TABLE 99 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
TABLE 100 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 126
TABLE 101 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 127
TABLE 102 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
TABLE 103 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 127
TABLE 104 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 128
TABLE 105 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 128
TABLE 106 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 129
TABLE 107 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 108 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 109 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 110 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 130
TABLE 111 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 131
TABLE 112 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 131
TABLE 113 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 131
TABLE 114 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
TABLE 115 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
TABLE 116 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 133
TABLE 117 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 118 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 119 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 120 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 134
TABLE 121 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 134
TABLE 122 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
TABLE 123 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 135
TABLE 124 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 125 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
TABLE 126 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 137
TABLE 127 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 128 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 129 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
TABLE 130 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 138
TABLE 131 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 138
TABLE 132 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
TABLE 133 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 139
TABLE 134 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
TABLE 135 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
TABLE 136 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 140

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: SEGMENTATION 23
FIGURE 2 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 26
FIGURE 3 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 27
FIGURE 4 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 31
FIGURE 8 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 33
FIGURE 9 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 38
FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 38
FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 42
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC PEMPHIGUS VULGARIS MARKET 53
FIGURE 15 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 60
FIGURE 16 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 61
FIGURE 17 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 61
FIGURE 18 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 62
FIGURE 19 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 71
FIGURE 20 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 72
FIGURE 21 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 72
FIGURE 22 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 73
FIGURE 23 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 78
FIGURE 24 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 79
FIGURE 25 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 79
FIGURE 26 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 80
FIGURE 27 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 85
FIGURE 28 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 86
FIGURE 29 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 86
FIGURE 30 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 87
FIGURE 31 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 92
FIGURE 32 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 93
FIGURE 33 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 93
FIGURE 34 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 94
FIGURE 35 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 94
FIGURE 36 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 140

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ